title: Multiple sclerosis: where will we be in 2020?
abstract: The past decade has seen a surge of research interest in multiple sclerosis and an accelerated expansion of investigative efforts into multiple sclerosis therapeutics. Investigators have continued dissecting the complex immunological perturbations that may contribute to the disease and made major advances in understanding the genetics of multiple sclerosis. This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade.
authors.affiliation: Mount Sinai School of Medicine, New York, NY, USA. aaron.miller@mssm.edu
authors.forename: Aaron E
authors.initials: AE
authors.lastname: Miller
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005544:Forecasting; D036281:Genetic Research; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology; D011379:Prognosis; D012106:Research / Q000639:trends*; D013116:Spinal Cord / Q000098:blood supply*; D014689:Venous Insufficiency / Q000150:complications / Q000503:physiopathology; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014807:Vitamin D; D016899:Interferon-beta